Peptide Therapeutics Market Updates

Peptide Therapeutics Market size was valued at USD 43.11 Billion in 2023 and is poised to grow from USD 45.67 Billion in 2024 to USD 72.46 Billion by 2032, growing at a CAGR of 5.94% during the forecast period (2025-2032).

Peptide therapeutics providers around the world are estimated to focus on research to maximize their business potential and stay competitive. Developing new therapeutics for different diseases indications will also be a preferred strategy for new as well as leading peptide therapeutics companies. Taking advantage of supportive government initatives to promote medical R&D will also create new opportunities in the future. 'Eli Lilly and Company ', 'Amgen Inc. ', 'Pfizer Inc. ', 'Bristol-Myers Squibb Company ', 'Novo Nordisk A/S ', 'Takeda Pharmaceutical Company Limited ', 'AstraZeneca PLC ', 'Sanofi SA ', 'GlaxoSmithKline PLC ', 'Novartis AG ', 'Zealand Pharma A/S ', 'AmbioPharm Inc. ', 'Bachem Holding AG ', 'PolyPeptide Group ', 'Circle Pharma, Inc. ', 'PeptiDream Inc. ', 'Apitope Technology Ltd. ', 'Ever Neuro Pharma GmbH ', 'Teva Pharmaceuticals Industries Ltd. ', 'Arch Biopartners Inc.'

Poor lifestyle choices and growing adoption of unhealthy habits have lead to a major surge in incidence of chronic diseases around the world. As prevalence of diabetes, cancer, and other diseases rises, so does the need for better treatment for the same also rises. Low toxicity of peptide therapeutics makes them a preferred choice for treatment for multiple chronic diseases.  

Development of Oral Peptide therapeutics: Peptide therapeutics companies can focus on the development of oral peptide therapeutics which are currently not widely available in the market. Heavy investments in research would be required to develop peptide therapeutics that can be administered orally but will pay of big time for any company who dives into this  peptide therapeutics market trend going forward.  

North America is estimated to secure the top spot when it comes to the peptide therapeutics market. Increasing incidence of chronic diseases and high investments in medical research are forecasted to be the key factors contributing to the dominance of this region. Presence of key pharmaceutical manufacturers, rising awareness regarding benefits of peptide therapeutics, and supportive government funding to boost medical R&D are also expected to bolster sales of peptide therapeutics in this region. The United States is projected to lead the demand for peptide therapeutics in North America followed by Canada.